Pfizer intends to raise up to $1.5 billion from Blackstone to develop an experimental drug to treat obesity. The funding is expected to continue until 2028, and a key feature of the developed treatment is the expected monthly regimen.
The funds are intended specifically for research and experimental work, and not for expanding sales of the finished drug. The amount of 1.5 billion dollars is defined as the upper limit of the funding: this does not mean that the entire amount has already been transferred. The collaboration gives Pfizer additional financial resources to advance the project over the coming years.
Monthly treatment is the goal of development, as the drug remains experimental. Neither the amount of funds raised nor the participation of a large investor in itself makes it a registered treatment. The deal shows how much significant investment the company is willing to devote to creating a new anti-obesity drug even before the development is complete.
Ξeconomics.